Profound understanding of the reimbursement environment and involved parties leads to rewarding negotiations and long-term success.
Higher life expectancy, changing age structures, health as a meritocracy, as well as the future economic demands on social systems define health and attitudes to health increasingly differently and more diverse. Re-allocation of risk across the value chain (pay for performance, capitation models, incentivized hygiene improvements, etc.) are emerging and starting to change the existing reimbursement schemes.
Products, services and therapies must provide real health economic benefits. Despite the trend to more standardization in global healthcare markets demands are still formed by customers and their needs. Therefore, it is pivotal to better understand the specifics of a target market segment and plan and act, accordingly.
Strategies Market Entry
Ease of access is determining our support activities. We help our customers to design the market introduction of products and services, pharmaceuticals, medical devices or new therapeutic procedures and accompany them from the actual product development and planning to all necessary regulations regarding market, regulatory, legal and re-imbursement situations.
Due to increasing regulatory requirements and recent health policy interventions in the healthcare markets, successful product launches have become more demanding. We are used to working in interdisciplinary teams and on topics that connect the fields of science, patient safety and economics. We provide special strategic concepts and a sophisticated definition of the best market entry strategy. In addition to the orientation to the right and important stakeholders and partners, we also provide a sound health economic expertise.
Strategies for reimbursement
Without an adequate reimbursement, innovations are bound to fail. That’s why we strongly support the negotiation of fair and adequate reimbursement of new products or services as well as the remuneration for the development and implementation of new business models, e.g. through NUB applications.
The development and preparation of internationally agreed market entry strategies and price reference regulation analyses are key factors for our reimbursement success. Our strategies are based on our confidential and profound discussions with decision-makers in the context of sounding boards and interviews with stakeholders and lead to contract models with payers and insurance companies.
Strategies for cost reduction
Next to the general therapeutic challenges that healthcare systems are facing, are the medical and financial burdens of healthcare acquired infections. The challenge is made even more difficult as healthcare systems are facing budget pressure in many countries and additionally, the increase in multidrug resistant bacteria is worsening the situation.
In addition to the human suffering, healthcare acquired infections involve considerable health-economic problems: hospital stays become longer and diagnosis and treatment become more complicated and are associated with extra costs. Postoperative surgical site infections, blood-stream infections or ventilator associated infections, for example, cause millions of additional hospital days per year. Apart from insurance companies, a significant part of these costs has to be covered by the medical facilities, because they are not totally refunded.
Subsequently, infection prevention is becoming increasingly important. Hygiene measures help to prevent infections and reduce antimicrobial use and have a significant influence on health and the financial situation of service providers and payers. Prevented infections can save substantial amounts of money for payers and healthcare providers and avoid unnecessary human suffering.